GSK PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,511 GBX | +0.02% |
|
-0.92% | +4.26% |
| 10:28am | UBS cuts GSK; RBC raises Melrose Industries | AN |
| 10:14am | GSK : UBS downgrades its recommendation | CF |
| Sales 2024 * | 31.61B 40.51B | Sales 2025 * | 33.62B 43.09B | Capitalization | 61.62B 78.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.43B 6.95B | Net income 2025 * | 6.44B 8.26B | EV / Sales 2024 * | 2.33 x |
| Net Debt 2024 * | 11.95B 15.31B | Net Debt 2025 * | 8.3B 10.64B | EV / Sales 2025 * | 2.08 x |
| P/E ratio 2024 * |
11.5
x | P/E ratio 2025 * |
9.64
x | Employees | 70,212 |
| Yield 2024 * |
4.02% | Yield 2025 * |
4.17% | Free-Float | 94.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on GSK plc
More press releases
| 1 day | -0.02% | ||
| 1 week | -0.92% | ||
| Current month | -1.14% | ||
| 1 month | -6.72% | ||
| 3 months | -6.67% | ||
| 6 months | -2.39% | ||
| Current year | +4.26% |
1 week
1 486.00
1 535.50
1 month
1 484.001 640.50
Current year
1 453.201 823.50
1 year
1 302.601 823.50
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Managers | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 21 M€ | +10.60% | - | |
| 2.51% | 7 M€ | +8.64% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-08 | 1,511 | +0.00% | 649 680 |
| 24-07-05 | 1,511 | +0.03% | 8,159,309 |
| 24-07-04 | 1,510 | +0.47% | 3,952,157 |
| 24-07-03 | 1,504 | 0.00% | 9,870,467 |
| 24-07-02 | 1,504 | -1.47% | 7,042,481 |
Delayed Quote London S.E., July 08, 2024 at 05:00 am EDT
More quotes
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.11
GBP
Average target price
20.17
GBP
Spread / Average Target
+33.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.26% | 78.92B | |
| +56.89% | 823B | |
| +40.42% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +14.04% | 239B | |
| +14.32% | 220B | |
| -0.37% | 219B | |
| +7.94% | 167B |
- Stock Market
- Equities
- GSK Stock
